Wall Street Zen Upgrades Celcuity (NASDAQ:CELC) to “Hold”

Celcuity (NASDAQ:CELC) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

CELC has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Stifel Nicolaus increased their target price on Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC reissued a “buy” rating and set a $122.00 price target on shares of Celcuity in a report on Thursday. Wolfe Research restated an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Finally, Jefferies Financial Group upped their price objective on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity presently has an average rating of “Moderate Buy” and an average target price of $109.88.

Celcuity Stock Performance

NASDAQ CELC opened at $106.02 on Friday. The firm has a 50-day moving average of $109.49 and a 200-day moving average of $91.20. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. The stock has a market cap of $5.13 billion, a PE ratio of -27.97 and a beta of 0.38. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, sell-side analysts anticipate that Celcuity will post -2.62 EPS for the current year.

Insider Activity

In other Celcuity news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.78% of the stock is currently owned by insiders.

Institutional Trading of Celcuity

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Celcuity by 23.5% in the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after purchasing an additional 391,262 shares in the last quarter. New York State Common Retirement Fund grew its position in Celcuity by 68.0% in the third quarter. New York State Common Retirement Fund now owns 47,704 shares of the company’s stock valued at $2,357,000 after acquiring an additional 19,313 shares during the last quarter. Atle Fund Management AB acquired a new stake in Celcuity in the third quarter valued at approximately $1,836,000. Candriam S.C.A. grew its holdings in shares of Celcuity by 48.3% during the third quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock worth $19,312,000 after purchasing an additional 127,348 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Celcuity by 2,142.0% in the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock worth $772,000 after purchasing an additional 14,930 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.